Cargando…

Alopecia secondary to anti-tumor necrosis factor-alpha therapy()

Biologic drugs represent a substantial progress in the treatment of chronic inflammatory immunologic diseases. However, its crescent use has revealed seldom reported or unknown adverse reactions, mainly associated with anti-tumor necrosis factor (anti-TNF). Psoriasiform cutaneous reactions and few c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Lara Beatriz Prata, Rego, Juliana Carlos Gonçalves, Estrada, Bruna Duque, Bastos, Paula Raso, Piñeiro Maceira, Juan Manuel, Sodré, Celso Tavares
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371673/
https://www.ncbi.nlm.nih.gov/pubmed/25830994
http://dx.doi.org/10.1590/abd1806-4841.20153084
Descripción
Sumario:Biologic drugs represent a substantial progress in the treatment of chronic inflammatory immunologic diseases. However, its crescent use has revealed seldom reported or unknown adverse reactions, mainly associated with anti-tumor necrosis factor (anti-TNF). Psoriasiform cutaneous reactions and few cases of alopecia can occur in some patients while taking these drugs. Two cases of alopecia were reported after anti-TNF therapy. Both also developed psoriasiform lesions on the body. This is the second report about a new entity described as 'anti-TNF therapy-related alopecia', which combines clinical and histopathological features of both alopecia areata and psoriatic alopecia. The recognition of these effects by specialists is essential for the proper management and guidance of these patients.